- Conditions
- Anesthesia
- Interventions
- Dexmedetomidine, Propofol (Group P), Propofol (Group DP)
- Drug
- Lead sponsor
- Keira Mason
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 3,096
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1-infection
- Interventions
- INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AC2993
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 219
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
- Drug
- Lead sponsor
- Lupin, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 34
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
- Conditions
- Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
- Interventions
- Testosterone
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Poor Energy Levels, Poor Metabolism, Difficulty With Weight Management, Bloating
- Interventions
- Love Wellness Energize
- Dietary Supplement
- Lead sponsor
- Love Wellness
- Industry
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Hypothermia
- Interventions
- Selection of anesthetic induction technique
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kaposi Sarcoma
- Interventions
- PDS01ADC, M7824
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more
- Conditions
- Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence, Alcohol-Related Disorders
- Interventions
- Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Placebo, Peppermint Oil, masking flavor
- Dietary Supplement · Other
- Lead sponsor
- Endourage, LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Novato, California
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 821 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more
- Conditions
- Gestational Diabetes
- Interventions
- Exenatide, Buccal/blood Sample Collection
- Drug · Genetic
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- HIV Infections
- Interventions
- CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Palo Alto, California + 13 more
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- Roflumilast
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 35
- States / cities
- Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 32 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- azelastine hydrochloride and fluticasone propionate, Dymista vehicle
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Cancer
- Interventions
- Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
- Radiation · Drug · Biological
- Lead sponsor
- Drexel University College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy
- Interventions
- Liothyronine, Sodium
- Drug
- Lead sponsor
- Ipe, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Neonatal Abstinence Syndrome
- Interventions
- Clonidine HCL
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- Up to 14 Days
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Plaque Psoriasis
- Interventions
- calcitriol ointment, placebo comparator
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more
- Conditions
- Oxygen Administration During Deep Sedation
- Interventions
- Nasopharyngeal catheter, Nasal Cannula, Oxygen Supplementation, Sedation
- Device · Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Asthma
- Interventions
- fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more